文献速递胸部肿瘤放疗

前瞻性评估大型州级质量协作组中局限期小细胞肺癌放疗分割方案的使用与急性毒性

Prospective Evaluation of Limited-Stage Small Cell Lung Cancer Radiotherapy Fractionation Regimen Usage and Acute Toxicity in a Large Statewide Quality Collaborative.
PubMed 文献 · Pract Radiat Oncol · 2023-04-24

在密歇根放射肿瘤质量协作组29家机构2012至2021年前瞻性收集的局限期小细胞肺癌患者中,78例(15.6%)接受每日两次放疗、421例接受每日一次放疗;按治疗中心分层并调整患者因素后,每日一次组因毒性导致治疗中断的比值是每日两次组的4.11倍(95%CI 1.31-12.87)。

要点

  • 每日两次放疗仅占15.6%(78例),每日一次为421例。
  • 每日一次放疗毒性高峰在放疗期间,每日两次毒性高峰在放疗后1个月内。
  • 调整后每日一次组因毒性中断治疗的比值比为4.11(95%CI 1.31-12.87)。

核心结论

  • 尽管缺乏每日一次放疗疗效更优或毒性更低的证据,局限期小细胞肺癌的超分割放疗仍不常被处方。
  • 鉴于真实世界实践中每日两次分割放疗后急性毒性高峰出现于放疗后且治疗中断可能性更低,作者认为提供者可开始更频繁地使用超分割放疗。

研究设计与样本

  • 密歇根放射肿瘤质量协作组29家机构于2012至2021年前瞻性收集局限期小细胞肺癌患者的人口学、临床和治疗数据及医生评估毒性和患者报告结局。
  • 采用多水平logistic回归按治疗中心聚类分析放疗分割及其他患者层面变量对因毒性导致治疗中断几率的影晌。
  • 按美国国家癌症研究所不良事件通用术语标准4.0版纵向比较两组方案≥2级毒性发生率。

主要发现

  • 78例(总体15.6%)接受每日两次放疗,421例接受每日一次放疗。
  • 每日两次放疗组已婚或与他人同住比例65% vs 每日一次组51%(P=0.019),无主要合并症比例24% vs 10%(P=0.017)。
  • 每日一次放疗毒性高峰在放疗期间,每日两次放疗毒性高峰在放疗后1个月内。
  • 按治疗中心分层并调整患者层面变量后,每日一次组因毒性导致治疗中断的比值比为4.11(95%CI 1.31-12.87),高于每日两次组。

临床怎么用

  • 作者认为,鉴于真实世界实践中每日两次分割放疗后急性毒性高峰出现于放疗后且治疗中断可能性更低,提供者可开始更频繁地使用超分割放疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: National guidelines on limited-stage small cell lung cancer (LS-SCLC) treatment give preference to a hyperfractionated regimen of 45 Gy in 30 fractions delivered twice daily; however, use of this regimen is uncommon compared with once-daily regimens. The purpose of this study was to characterize the LS-SCLC fractionation regimens used throughout a statewide collaborative, analyze patient and treatment factors associated with these regimens, and describe real-world acute toxicity profiles of once- and twice-daily radiation therapy (RT) regimens. METHODS AND MATERIALS: Demographic, clinical, and treatment data along with physician-assessed toxicity and patient-reported outcomes were prospectively collected by 29 institutions within the Michigan Radiation Oncology Quality Consortium between 2012 and 2021 for patients with LS-SCLC. We modeled the influence of RT fractionation and other patient-level variables clustered by treatment site on the odds of a treatment break specifically due to toxicity with multilevel logistic regression. National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0, incident grade 2 or worse toxicity was longitudinally compared between regimens. RESULTS: There were 78 patients (15.6% overall) treated with twice-daily RT and 421 patients treated with once-daily RT. Patients receiving twice-daily RT were more likely to be married or living with someone (65% vs 51%; P = .019) and to have no major comorbidities (24% vs 10%; P = .017). Once-daily RT fractionation toxicity peaked during RT, and twice-daily toxicity peaked within 1 month after RT. After stratifying by treatment site and adjusting for patient-level variables, once-daily treated patients had 4.11 (95% confidence interval, 1.31-12.87) higher odds of treatment break specifically due to toxicity than twice-daily treated patients. CONCLUSIONS: Hyperfractionation for LS-SCLC remains infrequently prescribed despite the lack of evidence demonstrating superior efficacy or lower toxicity of once-daily RT. With peak acute toxicity after RT and lower likelihood of a treatment break with twice-daily fractionation in real-word practice, providers may start using hyperfractionated RT more frequently.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Allen SG, Dragovic AF, Yin HM, et al. Prospective Evaluation of Limited-Stage Small Cell Lung Cancer Radiotherapy Fractionation Regimen Usage and Acute Toxicity in a Large Statewide Quality Collaborative. Pract Radiat Oncol. 2023. PMID: 37100388. doi:10.1016/j.prro.2023.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。